Tseng, Yen-YuYen-YuTsengJYH-MING LIOUCheng, Wei-ChiehWei-ChiehChengHsu, Jing-TingJing-TingHsuHsu, Tsui-LingTsui-LingHsuMING-SHIANG WUWong, Chi-HueyChi-HueyWong2022-12-212022-12-212022-10-192296-2646https://scholars.lib.ntu.edu.tw/handle/123456789/626691Current treatment of Helicobacter pylori involves a triple therapy comprising one proton pump inhibitor and two other antibiotics; however, the outcomes are limited due to the existence of antibiotic resistant strains. We previously reported that moenomycin A, a cell-wall transglycosylase inhibitor, is highly active against multidrug-resistant Helicobacter pylori. Herein we show that combination of moenomycin A with the protein synthesis inhibitor clarithromycin or metronidazole can synergistically achieve almost 95% eradication of multidrug-resistant Helicobacter pylori. We also found that the moenomycin A-non-susceptible strains of Helicobacter pylori with deletion of transglycosylase exhibit moenomycin A hyposensitivity, faster growth and impaired biofilm formation compared to the parental strain. Overall, the combination of moenomycin A and clarithromycin or metronidazole to achieve a synergistic effect on different targets is a promising treatment for multidrug-resistant Helicobacter pylori.enhelicobacterantibioticscombinationmoenomycinpenicillin-binding protein knockout[SDGs]SDG3journal article10.3389/fchem.2022.897578363390342-s2.0-85141181673WOS:000888259900001https://api.elsevier.com/content/abstract/scopus_id/85141181673